Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Christian Hinrichs
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05639972CT.gov E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | — | Recruiting | — | — | — |
NCT06493019CT.gov Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer | — | Recruiting | — | — | — |
NCT05952947CT.gov HRYZ-T101 Injection for HPV18 Positive Solid Tumor | — | Recruiting | — | — | — |
NCT05787535CT.gov HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | — | Unknown | — | — | — |
NCT05686226CT.gov E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | — | Recruiting | — | — | — |
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT05122221CT.gov CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers | — | Unknown | — | — | — |
NCT04046133CT.gov Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus | — | Active Not Recruiting | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT02865135CT.gov Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT02919969CT.gov Pembrolizumab in Metastatic Anal Cancer | — | Completed | — | — | — |
NCT02628067CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | — | Active Not Recruiting | — | — | — |
NCT02280811CT.gov T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | — | Completed | — | — | — |
NCT01585428CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Anal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Christian Hinrichs | P2 | BB · 64 |
| Fluorouracilum | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Carboplatin | Dustin Deming | P3 | BB |
| Irinotecan | University of Cincinnati | P3 | BB |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P3 | BB |
| Muamycin | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Federation Francophone de Cancerologie Digestive | P3 | BB |
| Oxaliplatin | University of Cincinnati | P2/3 | B |
| Fludarabine | Christian Hinrichs | P2 | B |
+42 more in the Anal Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Anal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-anal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →